60岁以上成人血小板减少症患者较匹配对照的血液系统恶性肿瘤风险增加:是否应 upfront 骨髓评估?
国际学会对孤立性血小板减少症是否需要骨髓穿刺/活检(BMB)意见不一。该回顾性人群队列研究显示,≥60岁孤立性血小板减少症患者(血小板<100×10⁹/L,血红蛋白和白细胞正常)发生血液系统恶性肿瘤的风险显著高于对照(第1年HR 15.5,第2年起HR 5.3),支持在专科门诊评估时考虑包括BMB在内的诊断性检查。
要点
- ≥60岁孤立性血小板减少症患者血液系统恶性肿瘤风险较对照显著升高。
- 第1年HR 15.5(95%CI 11.3-21.4),第2年及以后HR 5.3(95%CI 4.4-6.6)。
- 风险升高在按性别、年龄、严重程度、持续时间及2周内糖皮质激素治疗分层后持续存在。
核心结论
- ≥60岁患者中孤立性血小板减少症与血液系统恶性肿瘤存在强关联。
- 该关联支持在门诊专科会诊时考虑包括BMB在内的诊断性检查。
研究设计与样本
- 回顾性人群队列研究,纳入2009年1月1日至2019年12月31日期间≥60岁患者。
- 暴露组:因血小板减少症专科会诊,血小板<100×10⁹/L,但血红蛋白和白细胞计数正常。
- 非暴露组:从未因血小板减少症专科会诊且血小板≥100×10⁹/L。
- 主要结局为血液系统恶性肿瘤诊断,采用竞争风险死亡模型分析。
- 暴露组4930例,非暴露组17556例。
主要发现
- 中位随访4.0年(IQR 2.2-6.7)期间,暴露组378/4930例(19.1/1000PY,95%CI 17.1-21.0)诊断为血液系统恶性肿瘤。
- 非暴露组204/17556例(2.5/1000PY,95%CI 2.2-2.8)诊断为血液系统恶性肿瘤。
- 第1年HR 15.5(95%CI 11.3-21.4,p<0.0001),第2年及以后HR 5.3(95%CI 4.4-6.6,p<0.0001)。
- 按性别、年龄、血小板减少严重程度或持续时间、以及会诊后2周内糖皮质激素治疗分层分析,关联持续存在。
临床怎么用
- 作者认为该关联支持在门诊专科会诊时考虑包括BMB在内的诊断性检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
International societies have conflicting recommendations on whether bone marrow aspirate/biopsy (BMB) is needed during workup for isolated thrombocytopenia. Our objective was to determine if thrombocytopenia in patients aged ≥60 years is associated with an increased incidence of haematological malignancy. We performed a retrospective population-based cohort study in patients aged ≥60 years between January 1, 2009 to December 31, 2019. Exposed patients had specialist consultation for thrombocytopenia, with platelet count <100 × 109/L, but normal haemoglobin and white blood cell count. Unexposed patients were those who never had specialist consultation for thrombocytopenia and whose platelets were ≥100 × 109/L. The primary outcome was the diagnosis of haematological malignancy using a competing risk of death model. During 4.0 years (IQR 2.2-6.7) of follow-up, 378/4930 exposed (19.1/1000PY, 95% CI 17.1-21.0), and 204/17556 unexposed patients (2.5/1000PY, 95% CI 2.2-2.8) were diagnosed with haematological malignancy (HR 15.5 (95% CI 11.3-21.4, p < 0.0001) in year 1, and 5.3 (95% CI 4.4-6.6, p < 0.0001) in years 2+). This finding persisted in analyses stratified by sex, age, severity, or duration of thrombocytopenia, and treatment with corticosteroids within 2 weeks of consultation. This study found a strong association between isolated thrombocytopenia and haematological malignancy in patients ≥60 years, supporting consideration of diagnostic testing including BMB during outpatient specialist consultation.
引用
- Vijenthira A, Wilton AS, Lee S, et al. Increased risk of haematological malignancy in adults over age 60 with thrombocytopenia compared with matched controls: Time for an upfront bone marrow evaluation? Br J Haematol. 2024. PMID: 39072725. doi:10.1111/bjh.19649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。